My research focuses on understanding the changes in redox metabolism in the development of chronic kidney disease in children. I specifically investigate the use of pharmaceuticals for the protection of superoxide-induced kidney damage. Recent data suggests the disruptions in redox metabolism that lead to the progression of chronic kidney disease effects structural brain development and results in neurocognitive deficits in children with kidney dysfunction. MRI data in children with chronic kidney disease shows abnormalities in the brain volumetric grey matter, as well as microstructural abnormalities, are correlated with lower performance in targeted tests of executive function, delayed language and motor skill development, and academic underachievement.